Background and Purpose-Nine-and 24-point prediction scores have recently been published to predict hematoma expansion (HE) in acute intracerebral hemorrhage. We sought to validate these scores and perform an independent analysis of HE predictors. Methods-We retrospectively studied 301 primary or anticoagulation-associated intracerebral hemorrhage patients presenting <6 hours post ictus prospectively enrolled in the Predicting Hematoma Growth and Outcome in Intracerebral Hemorrhage Using Contrast Bolus Computed Tomography (PREDICT) study. Patients underwent baseline computed tomography angiography and 24-hour noncontrast computed tomography follow-up for HE analysis. Discrimination and calibration of the 9-and 24-point scores was assessed. Independent predictors of HE were identified using multivariable regression and incorporated into the PREDICT A/B scores, which were then compared with existing scores. Results-The 9-and 24-point HE scores demonstrated acceptable discrimination for HE>6 mL or 33% and >6 mL, respectively (area under the curve of 0.706 and 0.755, respectively). The 24-point score demonstrated appropriate calibration in the PREDICT cohort (χ 2 statistic, 11.5; P=0.175), whereas the 9-point score demonstrated poor calibration (χ 2 statistic, 34.3; P<0.001). Independent HE predictors included spot sign number, time from onset, warfarin use or international normalized ratio >1.5, Glasgow Coma Scale, and National Institutes of Health Stroke Scale and were included in PREDICT A/B scores. PREDICT A showed improved discrimination compared with both existing scores, whereas performance of PREDICT B varied by definition of expansion. Conclusions-The 9-and 24-point expansion scores demonstrate acceptable discrimination in an independent multicenter cohort; however, calibration was suboptimal for the 9-point score. The PREDICT A score showed improved discrimination for HE prediction but requires independent validation. 
Stroke
November 2015 P rimary intracerebral hemorrhage (ICH) accounts for 5% to 20% of all strokes and is associated with high morbidity and mortality. 1 Hematoma expansion (HE) occurs in ≈30% of patients resulting in early neurological deterioration and poor long-term outcome. 2, 3 Rapid and reliable means of HE prediction in the acute setting are needed to guide potential medical and surgical therapies in addition to clinical research. 4 ,5 A 9-point clinical score was recently developed and validated for HE prediction of >6 mL or 33% with variables, including warfarin use, time to initial computed tomography (CT), ICH volume, and CT angiography (CTA) spot sign presence. 6 The score demonstrated acceptable discrimination in both derivation and validation cohorts, but requires external validation given the nonstandardized CT follow-up used in the retrospective analysis. 6 Independently, a 24-point clinical score (BRAIN) was derived and validated for HE (>6 mL) from substudies of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1 and 2). 7 Score items were similar but included recurrent ICH and intraventricular hemorrhage extension. The 24-point score demonstrated acceptable discrimination but was limited by lack of baseline CTA and spot sign designation; the most robust predictor of expansion to date. 8, 9 We sought to validate both HE prediction scores in an independent prospectively enrolled acute ICH multicenter cohort, with standardized baseline CTA and 24-hour noncontrast CT (NCCT). We also sought to perform an independent analysis of expansion predictors to potentially improve HE prediction scores.
Methods

Study Protocol
Data were retrospectively analyzed from the Predicting Hematoma Growth and Outcome in Intracerebral Hemorrhage Using Contrast Bolus CT (PREDICT) study, 8 a prospectively enrolled multicenter observational cohort study (12 centers in 6 countries) of acute primary or anticoagulant-associated ICH presenting <6 hours post ictus enrolled from June 24, 2006 to July 21, 2012 . Detailed inclusion and exclusion criteria have been described previously. 8 Baseline variables recorded included age, sex, history of diabetes mellitus, hypercholesterolemia, hypertension, prior ICH, antiplatelet/ anticoagulant use, mean arterial blood pressure, Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), hemoglobin, leukocyte count, platelet count, blood glucose, international normalized ratio (INR), and activated partial thromboplastin time. All patients underwent baseline NCCT and CTA with follow-up NCCT obtained 24 hours after the baseline study. Standard local institutional CT protocols were used consistent with a pragmatic observational study design. 10 All data were submitted to the coordinating center at the University of Calgary (Calgary, Canada). The study protocol was approved by the research ethics board at each participating center.
Imaging Analysis
Baseline and 24-hour NCCT parenchymal ICH volumes were analyzed with Quantomo, a semiautomated computerized planimetry software (Cybertrial Inc., Calgary, Canada) 11 and verified by a neurologist blinded to CTA. Similar to prior ICH expansion studies, [6] [7] [8] intraventricular hemorrhage volumes were not included in the study analysis. CTA was independently examined for spot sign presence by 2 experienced neuroradiologists blinded to follow-up NCCT and HE status. A standard definition of the spot sign was used. 8, 12 CTA images were viewed under optimal 'spot' windows (width 200, level 100) and spot sign number recorded. 10 Reader disagreements were resolved by consensus. ICH location and intraventricular hemorrhage presence were recorded from baseline NCCT images.
Statistical Analysis
For descriptive statistics, categorical variables are presented as percentages, and continuous variables are presented as medians with interquartile range. Wilcoxon rank sum and Fisher exact tests were used to test univariate associations for continuous and categorical variables, respectively, between included and excluded patients.
The 9-point 6 and 24-point 7 HE scores were calculated as previously described and summarized in Table 1 . For the 9-point score validation and our independent HE analysis, significant 24-hour HE was defined as >6 mL or >33%. 3, 8 For the 24-point BRAIN prediction score validation, a >6 mL definition was used. 7 A >6 and ≥12.5 mL definition 3 of HE was also explored for all scores. Discrimination of the HE scores was assessed using receiver operating characteristic curves and area under the curve (AUC). AUC >0.7 to 0.8, >0.8 to 0.9, and >0.9 to 1.0 were considered acceptable, excellent, and outstanding discrimination, respectively. AUC 95% confidence intervals (95% CI) were computed using 2000 stratified bootstrap replicates. Discrimination comparison between the scores and spot sign presence was assessed using pairwise nonparametric receiver-operating characteristic comparisons. Score calibration assessment was performed with the χ 2 goodness-of-fit test with lower P values indicating poor fit to the observed data. 13 The χ 2 statistic was calculated by adding the sum of (observed-expected) 2 /expected across each score strata. Strata with <5 cases of observed HE were collapsed with adjacent strata. Test for trends in proportions was assessed using the Cochrane-Armitage test.
An independent analysis of univariate and multivariable predictors of HE in the PREDICT cohort was assessed using logistic regression. ICH volume, NIHSS, and GCS were partitioned into categories previously shown to be predictive of HE and clinical outcome.
14-16 Impaired coagulation was defined as INR>1.5. 17 Time from onset to CT was examined as a continuous and categorical variable. Multivariable model fit and discrimination were assessed using the Akaike Information Criterion and AUC, respectively. First-order interactions and collinearity were assessed. After multivariable modeling, a score-based prediction rule for expansion was developed using the regression coefficient-based scoring method. 18 Probability of HE was assessed and stratified by the newly developed score. Score strata with <10% of the cohort were collapsed to facilitate accurate estimation of outcome probability. Discrimination of the new score compared with the 9-and 24-point scores was assessed.
Statistical significance was defined as P<0.05 for all tests. Statistical analyses were performed in R, version 3.1.1 (R Foundation, http://www.r-project.org/).
Results
Of 390 enrolled patients, 301 met the study eligibility criteria for HE analysis ( Figure) . Patient demographics are listed in Table I in the online-only Data Supplement. Of 301 patients, 97 (32.2%) had HE of >6 mL or >33%, 75 (24.9%) had HE>6 mL, and 53 (17.6%) had HE≥12.5 mL.
Excluded patients had a greater frequency of lobar or infratentorial ICH and intraventricular hemorrhage at baseline and larger baseline ICH volume, higher white blood cell and platelet count, and partial thromboplastin time.
Validation of 9-Point and 24-Point (BRAIN) Scores
The 9-point score demonstrated increasing probability of HE (>6 mL or 33%) with increasing score (P trend <0.001). For scores 2 through 8, probability of HE was 17.9% (30/168), 29.2% (7/24), 50.0% (11/22) , 55.6% (25/45), 50.0% (13/26), 69.2% (9/13), and 66.7% (2/3), respectively. No patients scored <2 as PREDICT only enrolled patients presenting <6 hours of ictus. No patients had a score of 9. Diagnostic performance of the 9-point score for HE prediction is listed in Table II in Supplement. HE probability by score categories of 2 to 3 and 4 to 8 were 19.3% (37/192) and 55.0% (60/109), respectively. AUC for HE>6 mL or 33%, >6 mL alone, and ≥12.5 mL alone was 0.706 (95% CI, 0.646-0.767), 0.761 (95% CI, 0.700-0.822), and 0.808 (95% CI, 0.746-0.870), respectively. The 9-point score demonstrated significantly improved AUC over the spot sign alone for all HE definitions (all P<0.05). Poor score calibration occurred in the PREDICT data set for prediction of HE>6 mL or 33% (χ 2 statistic, 34.3; P<0.001). The 24-point expansion score (BRAIN) demonstrated increasing HE risk (>6 mL) with increasing score (P trend <0.001). For 24-point score categories of 0 to 4, 4 to 8, 9 to 12, 13 to 16, and 17 to 24, probability of expansion of >6 mL was 4.9% (4/82), 17.6% (12/68), 33.9% (40/118), 64.0% (16/25), and 37.5% (3/8), respectively. Diagnostic performance for HE prediction is listed in Table III in the online-only Data Supplement. AUC for HE>6 mL, >6 mL or 33%, and ≥12.5 mL was 0.755 (95% CI, 0.695-0.815), 0.673 (95% CI, 0.611-0.736), and 0.761 (95% CI, 0.696-0.825), respectively. There was a weak trend toward improved discrimination for HE>6 mL compared with the spot sign alone (P=0.139). The 24-point score did not demonstrate improved discrimination for HE>6 mL or 33% and ≥12.5 mL compared with the spot sign alone (P>0.20). Appropriate score calibration was noted for HE>6 mL (χ 2 statistic, 11.5; P=0.175).
Independent Analysis of Expansion Predictors
Univariate analysis for HE>6 mL or 33% demonstrated significant associations with warfarin use, INR, time from onset to CT, NIHSS, GCS, ICH volume, and spot sign presence and number (all P<0.05). These variables were selected for further multivariable regression analysis. To avoid collinearity, ICH volume, GCS, and NIHSS were analyzed in independent multivariable models. Warfarin use and INR>1.5 were combined into a single variable of warfarin use or INR>1.5. Spot sign number was selected instead of spot sign presence because increasing number of spots are associated with higher risk of HE, and spot number has been shown to be as predictive of HE as other metrics, such as spot sign score. 10, 19 Warfarin use or INR 1.5 and spot sign number remained significantly associated with HE in all multivariable models (all P<0.05). Time from symptom onset to baseline CT was Based on the 2 models demonstrating greatest discrimination (Table 2) , 2 new HE prediction scores were developed, the PREDICT A and B score (Table 1) . Both prediction scores included warfarin use or INR>1.5, spot sign number, and time from symptom onset to baseline CT. PREDICT A and B included GCS and NIHSS, respectively, as covariates.
PREDICT A/B Performance
Probability of HE stratified by the PREDICT A and B scores is listed in Table 3 . Diagnostic performance of the PREDICT Scores is listed in Tables IV and V in the online-only Data Supplement, respectively. Graded increased risk with HE was noted with increasing score (P trend <0.001). Risk of expansion was low, 7.1% and 5.6%, with low PREDICT A (0-2) and B (0-5) scores, respectively, whereas patients in the highest risk categories had ≤70.0% (PREDICT A, 15-23) and 73.3% (PREDICT B, 21-28) HE risk.
AUC for HE>6 mL or 33%, >6 mL, and ≥12.5 mL for PREDICT A was 0.781 (95% CI, 0.726-0.837), 0.823 (95% CI, 0.767-0.879), and 0.856 (95% CI, 0.800-0.911), respectively. AUC for HE>6 mL or 33%, >6 mL, and ≥12.5 mL for PREDICT B was 0.771 (95% CI, 0.715-0.827), 0.804 (95% CI, 0.746-0.862), and 0.837 (95% CI, 0.781-0.894).
Both PREDICT A and B showed significantly improved AUC for HE>6 mL or 33% discrimination compared with the 9-and 24-point scores (all P<0.05). For HE>6 mL discrimination, PREDICT A demonstrated significantly improved discrimination over the 9-and 24-point scores, whereas PREDICT B showed a trends toward improved discrimination compared with the 9-point (P=0.054) and 24-point scores (P=0.110). For HE ≥12.5 mL discrimination, PREDICT A showed a trend toward improved discrimination over the 9-point score (P=0.076), whereas PREDICT B was not significantly improved over the 9-point score (P=0.224). PREDICT A and B were significantly improved over the 24-point score for HE≥12.5 mL discrimination (both P<0.05).
Discussion
We independently validated the 9-and 24-point HE scores demonstrating acceptable discrimination with AUC 0.706 and 0.755 for HE of >6 mL or 33% and >6 mL alone, respectively. The AUC for the 9-point score was significantly improved over the presence of the spot sign alone for all HE definitions, whereas the 24-point BRAIN score did not. The previously reported AUCs were similar to our results and suggest reasonably robust discriminative ability.
In contrast to the 24-point BRAIN score, the 9-point score demonstrated poor calibration in the PREDICT cohort most notable for scores of 2 to 5, where a higher proportion of patients with HE was observed ranging from 17.9% to 55.6% compared with derivation values of 7.7% to 35.4%. 6 A potential cause for poor calibration is cohort differences as PREDICT only included patients <6 hours from onset compared with 37.3% in the 9-point score derivation cohort. Appropriate calibration of the 24-hour BRAIN score likely reflects study population similarities, both recruiting patients <6 hours of onset with routine 24-hour CT follow-up. 6, 7, 21 are robust HE predictors. Although lower GCS and impaired consciousness were also identified as HE predictors, 20, 22, 23 the association between baseline GCS, NIHSS, and HE is infrequently reported in larger studies. [5] [6] [7] Lower GCS and greater NIHSS likely reflect larger ICH volume; a recognized predictor of HE 6,7,14 postulated because of greater secondary vessel injury (ie, avalanche effect). 24 As GCS and NIHSS are often collected clinically and were independent predictors, they were incorporated into PREDICT A and B scores, respectively. Similarly, inclusion of warfarin or INR>1.5 allows use of either variable if one is unavailable. Spot sign number was included over spot sign presence because of its improved HE risk stratification characteristics. 10 Presence of anticoagulation and spot sign number ≥2 were the strongest HE predictors and were accordingly assigned the greatest points in both scores.
Both PREDICT scores demonstrated acceptable discrimination for >6 mL or 33% and excellent discrimination for HE>6 and ≥12.5 mL. PREDICT A demonstrated improved discrimination over the 9-point score and 24-point score for all HE definitions except for HE≥12.5 mL in which there is a trend toward improved prediction over the 9-point score. PREDICT B demonstrated improved discrimination for HE>6 mL or 33% over the 9-and 24-point scores and of HE≥12.5 mL compared with 24-point score; however, this was less robust for other HE definitions. This, together with wider prevalence of GCS use than NIHSS among nonstroke physicians favors the use of PREDICT A.
The strength of this study is that it addresses limitations of prior prediction score derivation data sets, specifically lack of imaging protocol, including baseline CTA and routine 24-hour follow-up. Prospective enrollment from multiple centers in PREDICT increases the generalizability of the present results. Acute hemostatic ICH trials aimed at limiting early HE have highlight the need for improved patient selection. 25, 26 The validated and derived scores in this study facilitate improved identification of patients at highest risk for HE, which may impact neurointensive care unit admission and suitability for inclusion in clinical trials of hemostatic treatment or early surgery. [25] [26] [27] Patients at low risk of HE who are unlikely to benefit from hemostatic therapies may avoid potentially serious iatrogenic adverse effects. 28, 29 Patients at low risk of HE may also benefit from promising new neurosurgical techniques, including minimally invasive surgery with recombinant tissue-type plasminogen activator and catheter drainage, which requires hematoma volume stability. [30] [31] [32] The study limitations include lack of delayed contrast enhanced imaging, such as delayed CTA, postcontrast CT, or dynamic CT perfusion, all of which are shown to improve sensitivity and specificity for HE and outcome prediction. 33 The PREDICT Scores also apply only to supratentorial ICH because patients with infratentorial ICH were excluded from analysis given their differing management and prognostic implications. 15, 34 The cohort used to derive the PREDICT Scores was relatively limited in size and although the results are promising, this study requires independent validation. The need for CTA at baseline may preclude potential use in patients with known renal impairment and in centers where CTA is unavailable or not currently routinely performed in acute ICH. The 23 and 28 points required for full scoring of PREDICT may further limit widespread clinical use. However, this remains a similar concern for the 24-point score. Future use of mobile applications may facilitate calculation of the score. Given the prognostic significance of the spot sign and potential for spot sign mimics, adequate training on spot sign identification is required. 35 As clinical-and imaging-based parameters of HE risk emerge, established HE prediction rules require modification to better predict outcomes in individual patients with the goal of better selecting patients for existing and novel therapeutic interventions.
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